Amoéba

Executive Summary

Amoéba is a French greentech company pioneering natural biocontrol solutions derived from the amoeba Willaertia magna C2c Maky. Founded in 2019 and based in Chassieu, France, the company leverages the organism's inherent antifungal and antibacterial properties to develop applications across three key verticals: plant protection, water treatment, and human wound care. Its core discovery—a serendipitous finding of potent fungicidal activity during regulatory testing—positions the company to address critical needs in sustainable agriculture and infection control. By replacing chemical pesticides and antimicrobials with a biological alternative, Amoéba aligns with global trends toward eco-friendly and regulatory-compliant solutions. The platform technology is versatile, with the amoeba's mode of action providing a novel approach to combating resistant pathogens, a growing concern in both agriculture and healthcare. While still in early commercialization stages, the company's focus on multiple high-demand markets offers significant upside potential if key milestones are achieved.

Upcoming Catalysts (preview)

• Q2 2026CE Marking for Wound Care Product70% success
• Q3 2026Strategic Partnership for Agricultural Distribution60% success
• Q1 2027Regulatory Approval for Water Treatment Application50% success